IART: Q2 2026 delivered revenue growth, margin expansion, and reaffirmed full-year guidance
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw revenue of $419M (+0.8% YoY) and adjusted EPS of $0.56 (+24.4%), with margin expansion and improved cash flow. FY 2026 guidance was reaffirmed, with organic growth of 0.8%–3.3% and adjusted EPS of $2.40–$2.50, despite FX and tariff headwinds.Original document: Integra LifeSciences Holdings Corporation [IART] Slides Release — Jul. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw revenue of $419M (+0.8% YoY) and adjusted EPS of $0.56 (+24.4%), with margin expansion and improved cash flow. FY 2026 guidance was reaffirmed, with organic growth of 0.8%–3.3% and adjusted EPS of $2.40–$2.50, despite FX and tariff headwinds.
Original document: Integra LifeSciences Holdings Corporation [IART] Slides Release — Jul. 29 2026